Other

Boehringer Mannheim Gmbh

Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh

Ulrich Bogdahn

Karl-Hermann Schlingensiepen

Ludwig Aigner

Reimar Schlingensiepen

Wolfgang Brysch

Georg-Ferdinand Schlingensiepen

Frank-Peter Wachs

Beate Winner

Brigitte Kaluza

Jürgen Winkler

Reinhard Burrner

The present invention relates to the use of oligonucleotides for the preparation of a pharmaceutical composition for the prevention or treatment of a disease, wherein neurogenesis and/or neuroregeneration has a beneficial effect, in particular a disease like Morbus Alzheimer, Morbus Parkinson, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, Spinocerebellar Atrophies, Creutzfeldt Jakob Disease, Frontemporal Dementia, Morbus Pick, AIDS Dementia Complex, Vascular Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multisystem-Atrophy, Hallervorden Spatz Disease, Huntington's disease, Stroke, Traumatic Brain and spinal cord Injury, Retinitis Pigmentosa, Macular Degeneration, Glaucoma, Cochlea Degeneration, Depression, Schizophrenia, Multiple Sclerosis, and developmental neurodegeneration.

Inhibitors of TGF-R signaling for treatment of CNS disorders

Inhibitors of TGF-R-signaling for treatment of CNS disorders

Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-&#x3b2; (TGF-&#x3b2;) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.

Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-&#x3b2; (TGF-&#x3b2;)

Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-&bgr; (TGF-&bgr;) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.

Antisense-oligonucleotides for transforming growth factor-&bgr; (TGF-&bgr;)

Melanoma-inhibiting protein

Growing community of inventors

Wurzburg, Germany

Ulrich Bogdahn